|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
AU1991901A
(en)
*
|
1999-09-27 |
2001-05-10 |
Gabriele Pecher |
Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
|
|
ATE395930T1
(de)
*
|
1999-10-22 |
2008-06-15 |
Aventis Pasteur |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7449557B2
(en)
|
2000-06-02 |
2008-11-11 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
CA2416893A1
(en)
*
|
2000-07-31 |
2002-02-07 |
Aventis Pasteur Limited |
Modified cea and uses thereof
|
|
CA2420944A1
(en)
|
2000-08-30 |
2002-03-07 |
Chemocentryx, Inc. |
Inhibition of cmv infection and dissemination
|
|
EP2336339A3
(en)
|
2000-09-25 |
2011-09-14 |
The Regents of the University of Michigan |
Production of viral vectors
|
|
CA2437201C
(en)
|
2001-02-02 |
2008-11-18 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
AU2004280608B2
(en)
*
|
2002-04-09 |
2012-04-05 |
Sanofi Pasteur, Inc. |
Modified CEA/B7 vector
|
|
CN102370974B
(zh)
|
2002-12-16 |
2014-09-17 |
全球免疫股份有限公司 |
用于免疫治疗的基于酵母的疫苗
|
|
CA2537931A1
(en)
*
|
2003-09-05 |
2005-03-24 |
Dennis Panicali |
Multi-antigen vectors for melanoma
|
|
ES2623812T3
(es)
|
2003-11-12 |
2017-07-12 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Vectores a medida para tratar y prevenir cáncer pancreático
|
|
ES2476990T3
(es)
*
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
|
US20090156519A1
(en)
*
|
2003-12-23 |
2009-06-18 |
Aventis Pasteur, Inc. |
Modified KSA and Uses Thereof
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
CN1976946A
(zh)
*
|
2004-07-03 |
2007-06-06 |
财团法人牧岩生命工学研究所 |
诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
|
NZ601827A
(en)
*
|
2007-10-18 |
2014-01-31 |
Bavarian Nordic Inc |
Use of mva to treat prostate cancer
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
AU2008363648B9
(en)
*
|
2008-10-31 |
2013-08-22 |
Tremrx, Inc. |
Vaccination with poxvirus vectors via mechanical epidermal disruption
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
KR101781966B1
(ko)
*
|
2009-04-17 |
2017-09-27 |
글로브이뮨 |
암에 대한 병용 면역요법 조성물 및 방법
|
|
KR102049928B1
(ko)
|
2011-08-17 |
2019-11-28 |
글로브이뮨 |
효모-muc1 면역요법 조성물 및 그 용도
|
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
RU2671558C2
(ru)
|
2013-06-14 |
2018-11-02 |
Псайоксус Терапьютикс Лимитед |
Режим введения и составы для аденовирусов типа в
|
|
AU2014338864C1
(en)
|
2013-10-25 |
2020-07-16 |
Akamis Bio Limited |
Oncolytic adenoviruses armed with heterologous genes
|
|
CN105829537B
(zh)
*
|
2013-11-28 |
2020-09-22 |
巴法里安诺迪克有限公司 |
用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
CA2973109A1
(en)
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
|
KR102193635B1
(ko)
|
2015-01-09 |
2020-12-21 |
이투빅스 코포레이션 |
복합 면역요법을 위한 방법 및 조성물
|
|
WO2016172249A1
(en)
|
2015-04-20 |
2016-10-27 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
PE20180241A1
(es)
|
2015-04-30 |
2018-01-31 |
Psioxus Therapeutics Ltd |
Adenovirus oncolitico que codifica una proteina b7
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
US20210198689A1
(en)
*
|
2016-03-18 |
2021-07-01 |
Nant Holdings Ip, Llc |
Multimodal Vector for Dendritic Cell Infection
|
|
CN109890408A
(zh)
*
|
2016-05-27 |
2019-06-14 |
埃特彼塞斯公司 |
新表位疫苗组合物及其使用方法
|
|
CN119614520A
(zh)
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
JP2021514678A
(ja)
*
|
2018-03-06 |
2021-06-17 |
ペップバックス・インコーポレイテッド |
核酸分子およびそれを使用する方法
|
|
US20210290708A1
(en)
|
2018-09-21 |
2021-09-23 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|